United States 119th Congress Status: In Committee 58 R cosponsors

HR 685 — SAVE Moms and Babies Act of 2025

Last action — Referred to the House Committee on Energy and Commerce.

Track this bill free

No card. One bill, free forever — alerts when it moves.

  1. ✓
    Introduced
  2. 2
    In Committee
  3. 3
    Passed House
  4. 4
    Passed Senate
  5. 5
    To Executive
  6. 6
    Enacted

This bill is in committee in the House. Introduced January 23, 2025. It must pass committee before a floor vote.

Next likely step: a committee vote, then a floor vote in the House.

Prognosis

Stalled 26% · moderate confidence

Where this bill stands today.

Odds of enactment

Low

How often bills like it became law.

  • In Committee

    Current position in the legislative process.

  • 58 sponsors

    1 primary, 57 co-sponsors signed on.

  • Single-party support

    Sponsorship is currently within one party (58 R).

Prognosis reads this bill's own signals — stage, sponsorship breadth, committee status, recorded votes and cross-state momentum. Odds come from a model trained on which bills have become law.

Summary

Support And Value Expectant Moms and Babies Act of 2025 or the SAVE Moms and Babies Act of 2025This bill prohibits the Food and Drug Administration (FDA) from approving any new drug (either as a brand-name drug or a generic) intended to terminate a pregnancy and imposes additional restrictions on such drugs that are already approved.Under the bill, an already-approved drug intended to terminate a pregnancy may be dispensed to a patient only with a prescription. Furthermore, the FDA may not approve any labeling change that would authorize (1) using the drug after 70 days of gestation, or (2) dispensing the drug by any means other than in-person administration by the prescribing health care practitioner.The FDA must also impose additional restrictions on such already-approved drugs, including by (1) requiring the prescribing health care practitioner to receive a special certification, (2) prohibiting the practitioner from also acting as the dispensing pharmacist, and (3) requiring the practitioner to have the ability to provide surgical intervention to the patient.The bill also rescinds any investigational use exemption already granted to such a drug if the bill would have prohibited the FDA from granting the exemption. (Currently, the FDA may grant an exemption to certain market approval requirements if a drug is intended solely for use in safety and effectiveness investigations.)

Bill Text

Sections of law this bill changes

From the bill's own amending language, matched to the official United States Code (current through Public Law 119-124).

Also cites: 1 U.S.C. § 8, 21 U.S.C. § 355

How this bill changes current law

4 changes Share ↗

Compared against current U.S. Code AI-generated reading aid — verify against the official bill.

The bill prohibits the approval of new abortion drugs and imposes additional regulatory requirements on previously approved abortion drugs.

  • 21 U.S.C. 355

    (aa) Abortion Drugs.-- (1) Prohibitions.--The Secretary shall not approve-- (A) any application submitted under subsection (b) or (j) for marketing an abortion drug; or (B) grant an investigational use exemption under subsection (i) for-- (i) an abortion drug; or (ii) any investigation in which the unborn child of a woman known to be pregnant is knowingly destroyed.

    This addition prohibits the FDA from approving any applications for abortion drugs or granting investigational use exemptions for them.

  • 21 U.S.C. 355

    (2) Previously approved abortion drugs.--If an approval described in paragraph (1) is in effect for an abortion drug as of the date of enactment of the Support And Value Expectant Moms and Babies Act of 2025, the Secretary shall-- (A) not approve any labeling change-- (i) to approve the use of such abortion drug after 70 days gestation; or (ii) to approve the dispensing of such abortion drug by any means other than in-person administration by the prescribing health care practitioner;

    This requires the Secretary to impose restrictions on labeling changes for abortion drugs concerning gestation limits and administration methods.

  • 21 U.S.C. 355

    (3) Reporting on adverse events by other health care practitioners.--The Secretary shall require all other health care practitioners to report to the Food and Drug Administration any adverse events experienced by their patients that are connected to use of an abortion drug, excluding any individually identifiable patient information.

    This mandates additional reporting requirements for health care practitioners regarding adverse events linked to abortion drug usage.

  • 21 U.S.C. 355

    (5) Definitions.--In this section: (A) The term `abortion drug' means any drug, substance, or combination of drugs or substances that is intended for use or that is in fact used (irrespective of how the product is labeled) to intentionally kill the unborn child of a woman known to be pregnant, or to intentionally terminate the pregnancy of a woman known to be pregnant, with an intention other than-- (i) to produce a live birth; (ii) to remove a dead unborn child; or (iii) to treat an ectopic pregnancy.

    This provides a specific definition of 'abortion drug', clarifying what substances fall under the prohibition and regulatory requirements.

Action History

  1. Introduced in House

  2. Introduced in House

  3. Referred to the House Committee on Energy and Commerce.

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

1 sponsors · 57 co-sponsors · 489 not signed on

Sponsors (1)

Co-sponsors (57)

Not signed on (489)

489 members have not signed on to this bill.

Show all 489 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Subjects

civil-rights healthcare health-insurance
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

What does HR 685 do?
Support And Value Expectant Moms and Babies Act of 2025 or the SAVE Moms and Babies Act of 2025This bill prohibits the Food and Drug Administration (FDA) from approving any new drug (either as a brand-name drug or a generic) intended to terminate a pregnancy and imposes additional restrictions on such drugs that are already approved.Under the bill, an already-approved drug intended to terminate a pregnancy may be dispensed to a patient only with a prescription. Furthermore, the FDA may not approve any labeling change that would authorize (1) using the drug after 70 days of gestation, or (2) dispensing the drug by any means other than in-person administration by the prescribing health care practitioner.The FDA must also impose additional restrictions on such already-approved drugs, including by (1) requiring the prescribing health care practitioner to receive a special certification, (2) prohibiting the practitioner from also acting as the dispensing pharmacist, and (3) requiring the practitioner to have the ability to provide surgical intervention to the patient.The bill also rescinds any investigational use exemption already granted to such a drug if the bill would have prohibited the FDA from granting the exemption. (Currently, the FDA may grant an exemption to certain market approval requirements if a drug is intended solely for use in safety and effectiveness investigations.)
Who sponsors HR 685?
HR 685 is sponsored by Latta, Robert E. (Republican), Rouzer, David (Republican), Brecheen, Josh (Republican), Strong, Dale W. (Republican), Miller, Mary E. (Republican), Webster, Daniel (Republican), Finstad, Brad (Republican), Aderholt, Robert B. (Republican), Feenstra, Randy (Republican), Smith, Christopher H. (Republican), Fulcher, Russ (Republican), Flood, Mike (Republican), Mann, Tracey (Republican), Harris, Andy (Republican), Fong, Vince (Republican), Ellzey, Jake (Republican), Weber, Randy K. Sr. (Republican), McCormick, Richard (Republican), Moolenaar, John R. (Republican), Ogles, Andrew (Republican), Guest, Michael (Republican), Higgins, Clay (Republican), Palmer, Gary J. (Republican), Moore, Tim (Republican), Shreve, Jefferson (Republican), LaHood, Darin (Republican), Fitzgerald, Scott (Republican), Biggs, Sheri (Republican), Moore, Barry (Republican), Bost, Mike (Republican), Fedorchak, Julie (Republican), Thompson, Glenn (Republican), Cloud, Michael (Republican), Hageman, Harriet M. (Republican), Stutzman, Marlin A. (Republican), Rogers, Mike D. (Republican), Kelly, Mike (Republican), Hern, Kevin (Republican), Kennedy, Mike (Republican), Harrigan, Pat (Republican), Timmons, William R. (Republican), Houchin, Erin (Republican), Norman, Ralph (Republican), Smith, Adrian (Republican), Cline, Ben (Republican), Bean, Aaron (Republican), Clyde, Andrew S. (Republican), Steube, W. Gregory (Republican), Messmer, Mark B. (Republican), Cammack, Kat (Republican), Onder, Robert F. (Republican), McGuire, John J. (Republican), Hill, J. French (Republican), Wilson, Joe (Republican), Crank, Jeff (Republican), Walberg, Tim (Republican), Langworthy, Nicholas A. (Republican), and Downing, Troy (Republican).
What is the current status of HR 685?
This bill is in committee in the House. Introduced January 23, 2025. It must pass committee before a floor vote.
Where can I track HR 685?
Track HR 685 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on HR 685

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of HR 685

Last checked for changes 3 months ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →